Cas No.: | 420831-40-9 |
Chemical Name: | 3-(Azepan-1-ylsulfonyl)-N-(3-bromophenyl)benzamide |
Synonyms: | Ak 7;AK-7;3-(azepan-1-ylsulfonyl)-N-(3-bromophenyl)benzamide;C19H21BrN2O3S;308B6B695N;3-(1-azepanylsulfonyl)-N-(3-bromophenyl)benzamide;3-(azepane-1-sulfonyl)-N-(3-bromophenyl)benzamide;Oprea1_876929;MLS006011706;SIRT2 Inhibitor II, AK-7;HMS3740I05;HMS3886F07;BCP09325;BDBM50008859;s5914;Benzamide, N-(3-bromophenyl)-3-((hexahydro-1H-azepin-1-yl)sulfonyl)- |
SMILES: | BrC1=C([H])C([H])=C([H])C(=C1[H])N([H])C(C1C([H])=C([H])C([H])=C(C=1[H])S(N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])(=O)=O)=O |
Formula: | C19H21BrN2O3S |
M.Wt: | 437.3506 |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | AK-7 is a selective cell- and brain-permeable SIRT2 inhibitor, with an IC50 of 15.5 μM. |
In Vivo: | AK-7 (15 mg/kg/dose, i.p.) is brain-permeable in wild-type and HD mice[1]. AK-7 (10, 20 mg/kg, i.p.) improves the behavior and neuropathological phenotype and extends survival of R6/2 HD mice. AK-7 (20 mg/kg) ameliorates HD neuropathology in R6/2 mice. AK-7 also reduces the polyglutamine aggregation in R6/2 brain. In addition, AK-7 treated 140CAG mice show motor performance changes that parallel untreated wild-type mice, with the 20 mg/kg dose being most effective and significantly different from untreated 140CAG mice[2]. |
In Vitro: | AK-7 (10 μM) reduces cholesterol levels in naive N2a neuroblastoma cells and hippocampal slice cultures from wild-type mice. AK-7 (1 μM) shows neuroprotective effect of AK-7 in striatal Huntington’s disease (HD) neurons[1]. AK-7 (12.5 μM) decreases ratio of DA neurons in primary midbrain cultures[3]. |